PMID- 32077199
OWN - NLM
STAT- MEDLINE
DCOM- 20200422
LR  - 20231113
IS  - 1349-7006 (Electronic)
IS  - 1347-9032 (Print)
IS  - 1347-9032 (Linking)
VI  - 111
IP  - 4
DP  - 2020 Apr
TI  - Effects of MIR143 on rat sarcoma signaling networks in solid tumors: A brief 
      overview.
PG  - 1076-1083
LID - 10.1111/cas.14357 [doi]
AB  - Rat sarcoma (RAS) is a well-known oncogene that plays important roles in cancer 
      proliferation, cell survival and cell invasion. RAS exists as three major 
      isoforms, Kirsten rat sarcoma (KRAS), Harvey rat sarcoma (HRAS) and neuroblastoma 
      rat sarcoma (NRAS). Mutations of these genes account for approximately 30% of all 
      cancers. Among them, KRAS mutations are the most common, responsible for 85%, 
      followed by NRAS (12%) and HRAS (3%). Although the development of RAS inhibitors 
      has been explored for over the past decade, so far, no effective inhibitor has 
      been found. MicroRNA (miRNA) are a class of small non-coding RNA that control the 
      gene expression of pleural target genes at the post-transcriptional level. MiRNA 
      play critical roles in the physiological and pathological processes at work in 
      cancers, such as cell proliferation, cell death, cell invasion and metastasis. 
      MicroRNA-143 (MIR143) is known to function as a tumor suppressor in a variety of 
      cancers. One of its known mechanisms is suppression of RAS expression and its 
      effector signaling pathways, such as PI3K/AKT and MAPK/ERK. Within the last five 
      years, we developed a potent chemically modified MIR143-3p that enabled us to 
      elucidate the details of the KRAS signaling networks at play in colon and other 
      cancer cells. In this review, we will discuss the role of MIR143-3p in those RAS 
      signaling networks that are related to various biological processes of cancer 
      cells. In addition, we will discuss the possibility of the use of MIR143 as a 
      therapeutic drug for targeting RAS signaling networks.
CI  - (c) 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd 
      on behalf of Japanese Cancer Association.
FAU - Tokumaru, Yoshihisa
AU  - Tokumaru Y
AUID- ORCID: 0000-0003-2481-7739
AD  - Breast Surgery, Department of Surgical Oncology, Roswell Park Comprehensive 
      Cancer Center, Buffalo, New York.
AD  - Department of Surgical Oncology, Graduate School of Medicine, Gifu University, 
      Gifu, Japan.
FAU - Takabe, Kazuaki
AU  - Takabe K
AUID- ORCID: 0000-0002-6435-4241
AD  - Breast Surgery, Department of Surgical Oncology, Roswell Park Comprehensive 
      Cancer Center, Buffalo, New York.
AD  - Department of Surgery, University at Buffalo Jacobs School of Medicine and 
      Biomedical Sciences, The State University of New York, Buffalo, New York.
FAU - Yoshida, Kazuhiro
AU  - Yoshida K
AUID- ORCID: 0000-0003-1408-0104
AD  - Department of Surgical Oncology, Graduate School of Medicine, Gifu University, 
      Gifu, Japan.
FAU - Akao, Yukihiro
AU  - Akao Y
AUID- ORCID: 0000-0001-8902-5367
AD  - United Graduate School of Drug and Medical Information Sciences, Gifu University, 
      Gifu, Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200318
PL  - England
TA  - Cancer Sci
JT  - Cancer science
JID - 101168776
RN  - 0 (Antineoplastic Agents)
RN  - 0 (KRAS protein, human)
RN  - 0 (MIRN143 microRNA, human)
RN  - 0 (Membrane Proteins)
RN  - 0 (MicroRNAs)
RN  - EC 3.6.1.- (GTP Phosphohydrolases)
RN  - EC 3.6.1.- (NRAS protein, human)
RN  - EC 3.6.5.2 (HRAS protein, human)
RN  - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
SB  - IM
MH  - Antineoplastic Agents/*therapeutic use
MH  - Cell Proliferation/drug effects
MH  - GTP Phosphohydrolases/genetics
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Humans
MH  - Membrane Proteins/genetics
MH  - MicroRNAs/antagonists & inhibitors/*genetics
MH  - Mutation
MH  - Oncogenes/*genetics
MH  - Proto-Oncogene Proteins p21(ras)/genetics
MH  - Sarcoma/drug therapy/*genetics/pathology
MH  - Signal Transduction/genetics
PMC - PMC7156858
OTO - NOTNLM
OT  - AKT
OT  - ERK
OT  - KRAS positive circuit
OT  - MAPK
OT  - MIR143
OT  - PI3K
OT  - RAS
COIS- The authors declare no conflict of interest.
EDAT- 2020/02/23 06:00
MHDA- 2020/04/23 06:00
PMCR- 2020/04/01
CRDT- 2020/02/21 06:00
PHST- 2019/11/01 00:00 [received]
PHST- 2020/02/01 00:00 [revised]
PHST- 2020/02/14 00:00 [accepted]
PHST- 2020/02/23 06:00 [pubmed]
PHST- 2020/04/23 06:00 [medline]
PHST- 2020/02/21 06:00 [entrez]
PHST- 2020/04/01 00:00 [pmc-release]
AID - CAS14357 [pii]
AID - 10.1111/cas.14357 [doi]
PST - ppublish
SO  - Cancer Sci. 2020 Apr;111(4):1076-1083. doi: 10.1111/cas.14357. Epub 2020 Mar 18.